share_log

Gene Genetic Technologies Ltd Says Plans Continue To Be Focussed On Concierge Medicine Groups And Gaining Coverage From US Payer System

Benzinga Real-time News ·  Sep 2, 2022 20:06

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG", "GENE")), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA strategic operations with the following updates:

Strategic Highlights:

  • Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives
  • Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions
  • Commercial evaluations underway at 10 US medical/family practices
  • Re-engagement with 1,600 previous geneType US customers
  • Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders...
Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment